Medical Encyclopedia |
|
Other encyclopedia topics: | A-Ag Ah-Ap Aq-Az B-Bk Bl-Bz C-Cg Ch-Co Cp-Cz D-Di Dj-Dz E-Ep Eq-Ez F G H-Hf Hg-Hz I-In Io-Iz J K L-Ln Lo-Lz M-Mf Mg-Mz N O P-Pl Pm-Pz Q R S-Sh Si-Sp Sq-Sz T-Tn To-Tz U V W X Y Z 0-9 |
Contents of this page: | |
|
Definition Return to top
Carcinoid syndrome is a group of symptoms associated with carcinoid tumors -- tumors of the small intestine, colon, appendix, and bronchial tubes in the lungs.
Causes Return to top
Carcinoid syndrome is the pattern of symptoms sometimes seen in people with carcinoid tumors. These tumors are rare, and often slow growing.
Carcinoid syndrome occurs only 10% of the time, usually after the tumor has spread to the liver or lung.
These tumors release too much of the hormone serotonin, as well as several other chemicals that cause the blood vessels to open (dilate).
More carcinoid tumors are being diagnosed today than in the past.
Symptoms Return to top
Most carcinoid tumors have no symptoms. They only produce the syndrome about 10% of the time.
When symptoms do occur, they may include:
Sometimes symptoms are brought on by physical exertion, or eating or drinking things such as blue cheeses, chocolate, or red wine.
Exams and Tests Return to top
Most of these tumors are found during abdominal surgery.
A physical examination may show:
Tests may include:
Treatment Return to top
Surgery to remove the tumor is usually the first treatment. It can permanently cure the condition if the tumor is completely removed.
If the tumor has spread to the liver, treatment involves destroying the local blood supply or giving chemotherapy directly into the liver.
When the entire tumor cannot be removed, removing large portions of the tumor ("debulking") can help relieve the symptoms.
Sandostatin (octreotide) injections are sometimes given to people with advanced carcinoid tumors that cannot be removed with surgery. This drug can block and reverse tumor growth. Interferon is often given with octreotide to help stop tumor growth.
A serotonin antagonist may be prescribed to control diarrhea and poor absorption of nutrients from the intestines (malabsorption).
One of several combinations of chemotherapy may be given through a vein (IV) or by mouth. If one combination does not work, another combination may be effective. About one-third of patients benefit from chemotherapy.
Avoid alcohol, large meals, and foods high in tyramine (aged cheeses, avocado, many processed foods), because they may trigger symptoms.
Some common medicines, like selective serotonin reuptake inhibitors (SSRIs, such as Paxil, Serzone, and Prozac) may make symptoms worse by increasing levels of serotonin. However, do not stop taking these medicines unless your doctor tells you to do so.
Support Groups Return to top
Learn more about carcinoid syndrome and get support from:
Outlook (Prognosis) Return to top
The outlook in patients with carcinoid syndrome is different from the outlook in patients who have carcinoid tumors without the syndrome.
In people with the syndrome, the tumor has usually spread to the liver, which lowers the survival rate. People with carcinoid syndrome are also more likely to have a separate cancer (second primary tumor) at the same time.
The outlook is more favorable thanks to new treatment methods, such as Sandostatin.
Possible Complications Return to top
When to Contact a Medical Professional Return to top
Call for an appointment with your health care provider if you have symptoms of carcinoid syndrome.
Prevention Return to top
Treating the tumor reduces the risk of carcinoid syndrome.
References Return to top
Kulke MH. Clinical presentation and management of carcinoid tumors. Hematol Oncol Clin North Am. 2007;21:433-455.
Robertson RG, Geiger WJ, Davis NB. Carcinoid tumors. Am Fam Physician. 2006.74:429-434.
Update Date: 9/4/2008 Updated by: Sean O. Stitham, MD, private practice in Internal Medicine, Seattle, Washington; and James R. Mason, MD, Oncologist, Director, Blood and Marrow Transplantation Program and Stem Cell Processing Lab, Scripps Clinic, Torrey Pines, California. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.